Correction for Dixon and Hortobagyi, BMJ 320 (7233) 457-458.
BMJ 2000;320:1173 ( 29 April )

Correction

Treating young patients with breast cancer

Our system for collecting declarations of competing interests failed partially for this editorial by J M Dixon and G Hortobagyi (19 February, pp 457-8). Because the BMJ failed to send Dr Hortobagyi a form, we did not receive a statement on competing interests from him. His coauthor, however, did receive a form and stated "none declared." We now have a statement from Dr Hortobagyi (see below). We apologise to him and to readers for our oversight.

"GH has served on ad hoc advisory boards for Genentech, Bristol-Myers Squibb, Novartis, CTI, and Eli Lilly over the past five years. He has received honorariums for public speaking, usually in the context of continued medical education meetings, from Genentech, Bristol-Myers Squibb, Novartis, and Aventis. He or members of his group have received or currently receive research grants from Genentech, Bristol-Myers Squibb, Novartis, AstraZeneca, and Aventis."

© BMJ 2000
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?
Access jobs at BMJ Careers
Whats new online at Student BMJ